Highlights - Glucagon-like peptide 1 (GLP-1) is a target for the treatment of diabetes mellitus
The drug is being developed by Eli Lilly and Company, the same pharmaceutical manufacturer behind tirzepatide (Mounjaro), which has received MHRA approval in the UK for type 2 diabetes and, more recently, for weight management
Another patient with stomach sensitivity may not tolerate the same medication schedule
Understanding what to expect during semaglutide withdrawal helps set realistic expectations and prevent panic about a second shedding episode
PCR grade water was purchased from Alpha Teknova (Product number W3330, CAS No
Note changes in appetite, gastrointestinal symptoms, sleep, skin reactions, and weight so you can identify patterns and discuss them with your clinician if needed